The estimated Net Worth of Daniel J Mitchell is at least $26.4 Tausend dollars as of 2 May 2017. Mr. Mitchell owns over 11,000 units of ARCA biopharma Inc stock worth over $26,400 and over the last 10 years he sold ABIO stock worth over $0. In addition, he makes $0 as Director at ARCA biopharma Inc.
Daniel has made over 1 trades of the ARCA biopharma Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 11,000 units of ABIO stock worth $29,810 on 2 May 2017.
The largest trade he's ever made was buying 11,000 units of ARCA biopharma Inc stock on 2 May 2017 worth over $29,810. On average, Daniel trades about 1,375 units every 0 days since 2015. As of 2 May 2017 he still owns at least 11,000 units of ARCA biopharma Inc stock.
You can see the complete history of Mr. Mitchell stock trades at the bottom of the page.
Daniel J. Mitchell is Director of the Company. Mr. Mitchell founded and is a Manager of Sequel Venture Partners, L.L.C., a venture capital firm formed in January 1997. Prior to founding Sequel Venture Partners, Mr. Mitchell was a founder in 1986 of Capital Health Venture Partners, a health care focused venture capital firm, where he was a General Partner until 2006. On behalf of Sequel Ventures, Mr. Mitchell led the 1998 Series A financing that initially funded Myogen, Inc., a biopharmaceutical company focused on cardiovascular diseases, participated in subsequent financing rounds and served on the board of directors until Myogen was acquired in 2006. He served on the board of directors of Replidyne, Inc., a publicly-traded pharmaceutical company, from 2002 until the company was acquired in 2009. Mr. Mitchell currently serves on the board of directors of several private companies. Mr. Mitchell holds a B.S. from the University of Illinois and an M.B.A. from the University of California at Berkeley.
Daniel Mitchell is 58, he's been the Director of ARCA biopharma Inc since 2014. There are 7 older and 5 younger executives at ARCA biopharma Inc. The oldest executive at ARCA biopharma Inc is Dr. Michael R. Bristow M.D., Ph.D., 76, who is the Co-Founder, Pres, CEO & Director.
Daniel's mailing address filed with the SEC is 10170 CHURCH RANCH WAY, SUITE 100, WESTMINSTER, CO, 80021.
Over the last 16 years, insiders at ARCA biopharma Inc have traded over $9,048,465 worth of ARCA biopharma Inc stock and bought 3,605,825 units worth $6,507,167 . The most active insiders traders include Forest Baskett, Scott D Sandell und Anthony A. Jr. Florence. On average, ARCA biopharma Inc executives and independent directors trade stock every 54 days with the average trade being worth of $636,994. The most recent stock trade was executed by Henderson Group Plc Janus H... on 16 August 2024, trading 5,818 units of ABIO stock currently worth $17,047.
arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.
ARCA biopharma Inc executives and other stock owners filed with the SEC include: